; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP) There has been limited success in identifying prognostic biomarkers in prostate cancer. A partial explanation may be that insufficient emphasis has been put on clearly defining what type of marker or patient category a biomarker study aims to identify and how different cohort characteristics affect the ability to identify such a marker. In this article, the authors put forth the ABC model of prostate cancer, which defines 3 groups of patients with localized disease that an investigator may seek to identify: patients who, within a given time frame, will not develop metastases even if untreated (category A), will not develop metastases because of radical treatment (category B), or will develop metastases despite radical treatment (category C). The authors demonstrate that follow-up time and prostate-specific antigen screening intensity influence the prevalence of patients in categories A, B, and C in a study cohort, and that prognostic markers must be tested in both treated and untreated cohorts to accurately distinguish the 3 groups. The authors suggest that more emphasis should be put on considering these factors when planning, conducting, and interpreting the results from prostate cancer biomarker studies, and propose the ABC model as a framework to aid in that process.
INTRODUCTION
The clinical heterogeneity of prostate cancer combined with the morbidity and expense associated with its radical treatment generate challenges in disease management. Despite substantial efforts invested in identifying biomarkers to distinguish those patients likely to benefit from radical treatment, to the best of our knowledge few molecular biomarkers currently are used in standard practice. A partial explanation may be that no framework currently exists that can be used to clearly define what type of marker or patient category a biomarker study aims to identify, and how different cohort characteristics (follow-up time, prostate-specific antigen [PSA] screening intensity, etc) affect the ability to detect such a marker. For example, many biomarker studies aim to identify markers that distinguish indolent from lethal disease. However, a marker of indolent disease (if defined as a cancer that does not metastasize and kill the patient) may be different in a 75-year-old man with a screen-detected tumor compared with a 60-year-old man with a clinically detected tumor. Contrary findings across studies also might arise because some studies include untreated patients (ie, those undergoing observation or watchful waiting [WW] ) whereas others include radically treated patients (ie, those treated with radical prostatectomy [RP] or radiotherapy [RT] ) or a combination of the 2 groups, whereas prognostic biomarkers may perform differently in these settings.
In this article, we put forth the ABC model of prostate cancer, a framework for the categorization of patients with prostate cancer that can aid in the design and interpretation of prognostic biomarker studies and facilitate communication among clinicians and investigators. This article does not address bias in biomarker studies stemming from tumor/marker misclassification, whether due to tumor multifocality, tumor heterogeneity, imperfect biopsy procedures, different molecular techniques used across studies to assess marker status, or the fact that in most RP cohorts the biomarker is assessed in the RP specimen and not in the diagnostic biopsy, which represent important but distinct challenges for biomarker identification.
Definition of the ABC Patient Categories
The ABC model is based on the following premise: at the time of diagnosis, men with clinically localized prostate cancer can be divided into 3 distinct patient categories (although to which category the patient belongs is not known at the time of diagnosis). Category A indicates patients who will not, during a given time frame, develop metastatic disease or die of their cancer even if untreated; category B indicates patients who will not, during a given time frame, develop metastatic disease or die of their cancer because of radical treatment; and category C indicates patients who will, during a given time frame, develop metastatic disease or die of their cancer even if radically treated.
Ideally, it would be possible to identify biomarkers that distinguish each of the ABC patient categories (note that a biomarker can be any set of markers, including tumor, blood, and/or radiology markers.) A marker of category A is desirable to identify those patients with no need for treatment, a marker of category B specifies which patients would benefit from radical treatment either at the time of initial diagnosis or during active surveillance (ie, a "trigger" for treatment among men undergoing active surveillance), and a marker of category C could help to identify patients who are suitable for enrollment in clinical trials exploring, for example, the effect of adjuvant systemic treatment, or help to identify those patients who should not undergo radical treatment.
It should be noted that the ABC model has similarities with several previously proposed "models" and "frameworks," such as the analogy of turtles, rabbits, and birds attributed to Drs. Hinman and Lange, the "stage A to D figure" proposed by Whitmore, and the "type I-III framework" proposed by von Eschenbach.
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The Percentage of Category A, B, and C Patients in a Study Cohort
The percentage of category A, B, and C patients in a study cohort strongly hinges on 3 factors: 1) life expectancy, or age and comorbidity, which is a strong determinant of the lifetime remaining in which to develop metastatic disease; 2) length of study follow-up, because the natural history of prostate cancer is particularly long and patients would be overwhelmingly categorized as category A in a study with short follow-up; and 3) PSA screening intensity. Indeed, the primary objective of PSA screening is to diagnose patients in category B instead of category C.
Length of follow-up and PSA screening intensity are closely related. PSA screening adds a lead time of 8 to 12 years. 3 Hence, follow-up studies including men with PSA-detected tumors need a follow-up that is 8 to 12 years longer than studies including men with non-PSAdetected tumors for the results to be comparable.
Below, we estimate the impact of follow-up time and PSA screening intensity on the percentages of patients in categories A, B, and C within a study population. We leverage results from 2 randomized trials comparing WW/observation with RP: the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) trial, 4 in which only 5% of tumors were detected by screening (Lars Holmberg and Hans-Olov Adami, personal communication), and the Prostate Cancer Intervention versus Observation Trial (PIVOT), 5 in which 76% of the tumors were screen-detected. 6 Figure 1 shows the cumulative incidence of prostate cancer death at 18 years of follow-up from SPCG-4. According to Figure 1 , the population was comprised of 71% category A patients (100% minus the 18-year cumulative incidence of prostate cancer death among men treated with WW [29%]), 11% category B patients (the cumulative incidence of prostate cancer death among men treated with WW [29%] minus the cumulative incidence of prostate cancer death among men treated with RP [18%]), and 18% category C patients (the cumulative incidence of prostate cancer death among men treated with RP). The corresponding percentages of patients based on 18 years of follow-up for distant metastases were 62% for category A, 12% for category B, and 26% for category C. At 12 years of follow-up in SPCG-4, which to the best of our knowledge is the longest reported follow-up for PIVOT, the corresponding percentages of patients were 74% in category A, 7% in category B, and 19% in category C. 7 If we apply the same definitions as in SPCG-4 to the heavily screened population in PIVOT, the percentages of patients in categories A, B, and C were 92%, 3%, and 6%, respectively, based on the 12-year cumulative incidence of prostate cancer death, and 89%, 6%, and 5%, respectively, based on the 12-year cumulative incidence of bone metastases. The percentages of patients in the A, B and C categories in these 2 trials, based on the incidence of bone metastases, also are shown in Supporting Information Table 1 .
Identification of ABC Biomarkers From Follow-Up Studies
Markers that distinguish each of the A, B, and C patient categories would be of significant clinical usefulness. For example, if a man with a 15-year life expectancy is diagnosed with clinically localized prostate cancer, we would like to know (with a high degree of certainty) if he, within 15 years, will not develop metastases even if untreated (category A), will not develop metastases because of radical treatment (category B), or will develop metastases despite radical treatment (category C). It may be difficult to identify biomarkers that can uniquely identify these 3 sets of patients. Indeed, several biomarkers may rather distinguish patients with "indolent" tumors (category A) from patients with "aggressive" tumors (categories B and C). For example, a man with a tumor of Gleason score 10 may have a high risk of dying of prostate cancer within 15 years, but a Gleason score of 10 may not tell us whether the patient already has metastatic disease at the time of diagnosis (ie, we cannot determine whether he belongs to the category B or C patient group). It also is possible that some men with metastatic disease at the time of diagnosis would still benefit from radical treatment, in terms of survival time, because of local tumor control. The timeframe also is important. For example, a patient with a tumor of Gleason score 6 may have an excellent 15-year prognosis (ie, a category A marker for 15-year survival) but an unclear 30-year prognosis (ie, not a category A marker for 30-year survival).
For the following conceptual reasoning, we assumed that there exist 2 broad classes of markers: biomarkers that distinguish patients in category A from those in categories B/C and another class that uniquely identifies patients in categories A, B, and C. We also assumed a hypothetical "perfect" cohort with 100% follow-up, no competing causes of death, and100% biomarker accuracy.
Within WW cohorts, we can separate category A patients, those who survive their cancer even in the absence of radical treatment, from the group of category B plus C patients, who die of their cancer. Within RP/RT cohorts, we can separate category C patients, those who die of their cancer despite radical treatment, from patients in category A plus B, who survive. Thus, neither cohort is able to uniquely identify all 3 ABC categories. However, based on the results for a given biomarker from both the WW and RP/RT cohorts, it is possible to deduce whether it is likely to be a category A, B, C, or B/C marker.
Let us assume that we have identified a biomarker that perfectly discriminates patients with "indolent" disease (category A) from patients with "aggressive" disease (categories B/C). As shown schematically in Figure 2 Top, such a biomarker will be a more powerful predictor of poor outcomes in a WW cohort compared with an RP/ RT cohort. In a WW cohort, all men who die of prostate cancer will express the biomarker, whereas no men who survive their cancer will. In an RP/RT cohort, all men who die of the disease will express the biomarker, but so will a percentage (category B/category A plus B) of the men who survive.
Instead, let us assume we have identified biomarkers that can distinguish each of the ABC patient categories. Following the same reasoning as above, a category C marker will be a more powerful predictor of poor outcome in an RP/RT cohort versus a WW cohort, because all men in the RP/RT cohort who die of prostate cancer will express the biomarker, whereas only a percentage (category C/category B plus C) of the men who die of prostate cancer in the WW cohort will express the category C marker. However, a category B marker will appear as a marker of poor prognosis in a WW cohort, whereas it will appear as a marker of good prognosis in an RP/RT cohort; in a WW cohort, all men expressing the biomarker will die of prostate cancer, whereas in an RP/RT cohort, all men expressing the biomarker will survive (Fig. 2 Bottom). Hence, if a category B marker exists, it is expected that study results from conservatively treated patients will yield inverse associations compared with a study comprised of radically treated patients.
Thus, if a marker is associated with poor prognosis in a WW cohort, it may be a category B, C, or B/C marker, whereas if it is associated with a good prognosis it should be a category A marker. If a marker is associated with a poor prognosis in an RP/RT cohort, it may be a category C or B/C marker, whereas if it is associated with a good prognosis it may be a category A or B marker. This reasoning is analogous to identifying prognostic versus predictive markers in a standard randomized trial; to identify whether a marker is prognostic, predictive, or both, data regarding marker status and follow-up among both untreated and treated patients are needed.
As Supporting Information, we have provided a quantitative analysis of the power to detect category A, B, C, or B/C markers in treated and untreated cohorts, assuming biomarker sensitivities and specificities of <1.0 (eg, competing causes of death and imperfect biomarker accuracy due to, for example, tumor/marker misclassification) and patient prevalences of categories A, B, and C from SCPG-4 and PIVOT (see Supporting Information  Figs. 1-4) . We conclude that in these settings, category A markers may be consistently identified in both treated and untreated cohorts because the prevalence of category A patients overwhelms that of category B and C patients, especially in the PSA screening era, causing dilution by category B patients in treated cohorts to have a minimal effect on power. Conversely, the capacity to detect category B or C markers depends on cohort type. Importantly, the power to detect category B markers is limited in RP cohorts, especially in a cohort of patients with screen-detected tumors.
Examples From the Literature
Transmembrane protease, serine 2 (TMPRSS2):ETS transcription factor (ERG) the most common somatic event in prostate cancer, is present in approximately one-half of men treated with RP and in approximately one-quarter of men with prostate cancer that is detected during transurethral resection of the prostate (TURP). 8, 9 Among men undergoing RP, TMPRSS2:ERG is not associated with a poor prognosis. 9 Conversely, among men undergoing WW after a diagnosis of prostate cancer on TURP, TMPRSS2:ERG appears to be a marker of poorer prognosis. 9 Statistically, TMPRSS2:ERG thus behaves like a category B marker. There are several possible explanations for these diverging findings, including bias; for example, TMPRSS2:ERG-positive tumors in TURP samples may be biologically different from those detected in the peripheral zone after RP. However, it also is possible that TMPRSS2:ERG is a true category B marker and that the presence of TMPRSS2:ERG in an untreated cohort is associated with poor prognosis because it acts an indicator that the tumor has the capability to metastasize if left untreated, whereas if studied in a cohort restricted to those patients who underwent RP, it offers no prognostic value on its own (or even an association with improved outcomes) because it is not an indicator of occult metastases. A definite answer for this question requires study in a WW cohort assessing TMPRSS2:ERG in diagnostic biopsies rather than in TURP samples.
Another example comes from a reanalysis of the SPCG-4 trial data. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) of prostate cancer death at 10 years were presented for, among other factors, Gleason score (7 vs < 7) and age (<65 years vs 65 years) at the time of diagnosis stratified by randomization arm (RP or WW). 10 Although the results should be interpreted with caution given the rather low statistical power, Gleason score behaves similar to a category B/C marker, whereas age behaves as a category B marker; the HRs for Gleason score were similar in the RP versus WW arm (HR, 3 
Recommendations
To aid in the design and interpretation of prognostic biomarker studies, and to facilitate communication among clinicians and investigators, we recommend that the following factors are considered and, when appropriate, presented in future prognostic biomarker studies:
1. What type of patient category a marker aims to identify. 2. The follow-up time for which the marker may be relevant. 3. Key patient/cohort characteristics, including life expectancy (age and comorbidity) and whether tumors were detected by PSA. 4. To not discard null findings from treated cohorts if the marker may be a category B marker. 5. To test the marker in both treated and untreated cohorts for validation, depending on whether it is a category A, B, or C marker.
For example, a WW biomarker study with 10 years of follow-up including men with a life expectancy of 20 years and PSA-detected tumors may identify a marker that is expressed exclusively among men who survive their cancer. In that case, we suggest that such a marker is presented as a 10-year category A marker for men with PSAdetected tumors, rather than simply a marker of "indolent" disease (ie, to specify for which patient category, time frame, etc, the marker pertains).
Conclusions
By virtue of its simplicity, the ABC model of prostate cancer has limitations. Unique categorical separation of category A, B, and C patients is challenging in practice. Prognostic information is most often determined on a continuous scale, and classification into distinct risk groups requires additional consideration. The model also is based on assessing a biomarker at one time, and does not account for time-dependent changes in biomarker status. Furthermore, general cohort characteristics such as patient age, overall health, and length of follow-up can substantially impact the risk ratio and power calculations; our power analysis was limited to the SPCG-4 and PIV-OT settings and thus may not be valid in other settings. Moreover, our estimates of the percentage of category A, B, and C patients in PIVOT and SPCG-4, as well as our power analysis, was based on results from "intention-totreat" analyses, rather than from "per-protocol" or "astreated" analyses, which may have yielded different and more accurate estimates.
A lack of success in identifying prognostic biomarkers in patients with prostate cancer results largely from tumor/marker misclassification in combination with the complex tumor biology of prostate cancer. However, another contributor may be that insufficient emphasis has been put on clearly defining what type of marker or patient category a biomarker study aims to identify and how different cohort characteristics, including whether cohort members have been radically treated, affect the ability to identify such a marker. As we have shown in this article, such factors have important implications for study findings. We suggest that greater consideration be given to these factors when planning, conducting, and interpreting the results from prostate cancer biomarker studies, and put forth the ABC model as framework to aid in that process.
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